On May 4, 2023 Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, reported two presentations at the Protein Engineering Summit (PEGS) taking place May 15-19 in Boston as well as a poster presentation at the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting in Los Angeles May 16-20 (Press release, OrnaTherapeutics, MAY 4, 2023, View Source [SID1234631043]). Orna is presenting preclinical results for ORN-101, an in situ CAR program in development, as well as further details about its platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are paving the way for advancements in RNA therapeutics that reach beyond infectious disease to treat cancer and genetic disorders," said Robert Mabry, PhD, Chief Scientific Officer at Orna. "Our ORN-101 program demonstrates the benefits of our platform’s ability to create a paradigm-changing treatment with the characteristics we believe matter most to patients, including a rapid timeline from diagnosis to treatment, strong expression and tumor-killing potency at low dose, and a regimen without the harsh chemotherapeutic lymphodepletion protocols typically required for standard engineered cell therapies."
Details for the presentations are as follows:
PEGS presentations
Title: Synthetic Circular RNA as a New Therapeutic Modality
Speaker & Chair: Nelson Chau, PhD, Senior Vice President, Platform
Session: Innovating RNA Therapeutics
Time: Tuesday May 16, 4:30pm ET
Title: In situ CAR Therapy Using oRNA
Speaker: Amy Becker, PhD, Director of Immunology
Session: Cellular Reprogramming, Increasing Specificity
Time: Thursday, May 18, 1:50pm ET
ASGCT poster
Title: In situ CAR Therapy Using oRNA Lipid Nanoparticles Regress Tumors in vivo
Speaker: Akinola Emmanuel, PhD, Principal Scientist
Board: 1119
Time: Thursday, May 18, 12-2pm PT
About ORN-101:
ORN-101, Orna’s lead program, is an in situ CAR therapy designed to modify a patient’s immune cells inside their body. Comprising an oRNA molecule packaged inside a proprietary lipid nanoparticls (LNP) formulation, this easily redosable format could avoid patient lymphodepletion and allow for reliable dose control, overcoming barriers of existing ex vivo CAR-T therapies without sacrificing efficacy. Preclinical data demonstrates tumor suppression and eradication in an animal model, suggesting the possibility that oRNA-LNP based cancer therapies could eventually overtake cell therapies.